

Wee-Joo Chng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8415870/publications.pdf>

Version: 2024-02-01

313
papers

15,696
citations

28274

55
h-index

19749

117
g-index

317
all docs

317
docs citations

317
times ranked

19484
citing authors

#	ARTICLE	IF	CITATIONS
1	ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells. <i>Haematologica</i> , 2022, 107, 680-689.	3.5	12
2	CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. <i>Cancer Gene Therapy</i> , 2022, 29, 475-483.	4.6	38
3	T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. <i>PLoS ONE</i> , 2022, 17, e0261469.	2.5	0
4	THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1207.	4.1	4
5	Genomic characterization of functional high-risk multiple myeloma patients. <i>Blood Cancer Journal</i> , 2022, 12, 24.	6.2	16
6	p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). <i>Oncogene</i> , 2022, 41, 2106-2121.	5.9	3
7	Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma. <i>Cells</i> , 2022, 11, 941.	4.1	5
8	Effects of a Mindfulness Program on Stress and Psychological Outcomes Among Cancer Survivors: a Quasi-Experimental Study. <i>Mindfulness</i> , 2022, 13, 982.	2.8	1
9	A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of V β 9V γ 2 T cells. <i>Immunotherapy</i> , 2022, 14, 321-336.	2.0	4
10	Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma. <i>Cancer Research</i> , 2022, 82, 406-418.	0.9	18
11	Metabolic Vulnerabilities in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1905.	3.7	6
12	New immunotherapeutic target in myeloma. <i>Blood</i> , 2022, 139, 2417-2418.	1.4	4
13	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	5.0	24
14	V β 9V γ 2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. <i>PLoS ONE</i> , 2022, 17, e0267475.	2.5	5
15	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.2	1,023
16	The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. <i>Npj Digital Medicine</i> , 2022, 5, .	10.9	11
17	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
18	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , 2021, 35, 1797-1802.	7.2	14

#	ARTICLE	IF	CITATIONS
19	RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. <i>Oncogene</i> , 2021, 40, 746-762.	5.9	5
20	Daratumumab-induced transient myopic shift and its proposed mechanisms. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 81-83.	2.6	2
21	ADARs, RNA editing and more in hematological malignancies. <i>Leukemia</i> , 2021, 35, 346-359.	7.2	10
22	SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic <i>PTP4A3</i> through Chromatin Remodeling in t(4;14) Multiple Myeloma. <i>Cancer Research</i> , 2021, 81, 2332-2344.	0.9	10
23	Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer Progression. <i>Frontiers in Oncology</i> , 2021, 11, 559822.	2.8	12
24	Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 32.	6.2	14
25	Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3883-3906.	5.4	35
26	Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103211.	4.4	15
27	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
28	CAR T-cell therapy in multiple myeloma: more room for improvement. <i>Blood Cancer Journal</i> , 2021, 11, 84.	6.2	97
29	Single cell multiomic analysis and immune cell type profiling of multiple myeloma with t(4;14).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20013-e20013.	1.6	0
30	Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1702-1712.	4.1	14
31	A unique rhinologic manifestation of multiple myeloma. <i>Otolaryngology Case Reports</i> , 2021, 19, 100296.	0.1	0
32	Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. , 2021, 9, e002123.		8
33	Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore. <i>Nature Biotechnology</i> , 2021, 39, 1394-1402.	17.5	131
34	Chromatin interaction neural network (ChINN): a machine learning-based method for predicting chromatin interactions from DNA sequences. <i>Genome Biology</i> , 2021, 22, 226.	8.8	26
35	High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 143.	6.2	17
36	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). <i>Blood Cancer Journal</i> , 2021, 11, 150.	6.2	2

#	ARTICLE	IF	CITATIONS
37	Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. <i>Cancers</i> , 2021, 13, 5147.	3.7	4
38	Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103507.	4.4	3
39	Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 1358-1358.	1.4	1
40	Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes. <i>Blood</i> , 2021, 138, 2653-2653.	1.4	0
41	Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 1656-1656.	1.4	2
42	Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2209-2209.	1.4	0
43	Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies. <i>Blood</i> , 2021, 138, 1678-1678.	1.4	0
44	Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience. <i>Blood</i> , 2021, 138, 1921-1921.	1.4	0
45	Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 3776-3776.	1.4	1
46	Daratumumab Resistant Natural Killer/T-Cell Lymphoma Exhibit an Addiction to the Exosome Biogenesis Pathway for Survival. <i>Blood</i> , 2021, 138, 2256-2256.	1.4	15
47	Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE). <i>Blood</i> , 2021, 138, 3045-3045.	1.4	0
48	Mapbatch: Conservative Batch Normalization for Single Cell RNA-Sequencing Data Enables Discovery of Rare Cell Populations in a Multiple Myeloma Cohort. <i>Blood</i> , 2021, 138, 2954-2954.	1.4	2
49	Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study. <i>Blood</i> , 2021, 138, 720-720.	1.4	0
50	Bivalent Histone Modifications By ReiiBP Leads to Transcriptional Reprogramming and TLR7-BTK Driven IL-6 Pro-Inflammatory Response in t(4;14) Myelomagenesis. <i>Blood</i> , 2021, 138, 2202-2202.	1.4	4
51	Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 378-378.	1.4	0
52	IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. <i>Haematologica</i> , 2020, 105, 1391-1404.	3.5	34
53	ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 2286-2297.	3.5	43
54	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. <i>Lancet Oncology</i> , The, 2020, 21, 306-316.	10.7	49

#	ARTICLE	IF	CITATIONS
55	Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing. <i>Immunology and Cell Biology</i> , 2020, 98, 138-151.	2.3	6
56	Microenvironmental Hypoxia Induces Dynamic Changes in Lung Cancer Synthesis and Secretion of Extracellular Vesicles. <i>Cancers</i> , 2020, 12, 2917.	3.7	13
57	Rapid production of clinical-grade SARS-CoV-2 specific T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e101.	0.9	24
58	Targeting NF- κ B Signaling for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2203.	3.7	24
59	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. <i>Blood</i> , 2020, 135, 2337-2353.	1.4	49
60	circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia. <i>Haematologica</i> , 2020, 105, e343-e348.	3.5	7
61	Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study's Asian Subgroup Analysis. <i>Advances in Therapy</i> , 2020, 37, 3404-3416.	2.9	7
62	Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 8.	5.0	10
63	Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. <i>PLoS ONE</i> , 2020, 15, e0232068.	2.5	12
64	Immunotherapy in Multiple Myeloma. <i>Cells</i> , 2020, 9, 601.	4.1	27
65	Qualitative Study of Factors Affecting Patient, Caregiver and Physician Preferences for Treatment of Myeloma and Indolent Lymphoma. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 301-308.	1.8	8
66	NanoVar: accurate characterization of patients' genomic structural variants using low-depth nanopore sequencing. <i>Genome Biology</i> , 2020, 21, 56.	8.8	73
67	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 1759.	3.7	2
68	Immunoglobulin M Paraproteinaemias. <i>Cancers</i> , 2020, 12, 1688.	3.7	15
69	Lymphocyte cytosolic protein 1 (LCP1) is a novel TRAF3 dysregulation biomarker with potential prognostic value in multiple myeloma. <i>Genome Instability & Disease</i> , 2020, 1, 286-299.	1.1	5
70	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
71	Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 9.	6.2	22
72	Enabling Technologies for Personalized and Precision Medicine. <i>Trends in Biotechnology</i> , 2020, 38, 497-518.	9.3	169

#	ARTICLE	IF	CITATIONS
73	Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e165-e170.	0.4	3
74	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	7.2	17
75	Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 222-231.	1.1	8
76	Surgical Management of Multiple Myeloma With Symptomatic Involvement of the Spine. <i>International Journal of Spine Surgery</i> , 2020, 14, 785-794.	1.5	8
77	Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma. <i>Blood</i> , 2020, 136, 17-17.	1.4	1
78	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
79	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
80	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. <i>Trials. International Journal of Hematology</i> , 2019, 110, 466-473.	1.6	12
81	Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 77.	17.0	69
82	IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. <i>Cancer Research</i> , 2019, 79, 4679-4688.	0.9	53
83	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111755.	5.5	15
84	Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 897-910.	8.7	35
85	MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2019, 134, 2046-2058.	1.4	25
86	NOVEL ROLE OF PRL-3 PHOSPHATASE IN HEMATOLOGICAL MALIGNANCIES. <i>Experimental Hematology</i> , 2019, 76, S67.	0.4	0
87	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e470-e477.	0.4	3
88	STAT3: A Promising Therapeutic Target in Multiple Myeloma. <i>Cancers</i> , 2019, 11, 731.	3.7	54
89	Molecular pathogenic pathways in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 33.	17.0	82
90	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	1.8	9

#	ARTICLE	IF	CITATIONS
91	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S19-S20.	2.0	4
92	EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 118.	17.0	62
93	Synthetic lethality in multiple myeloma harboring double oncogenic hits of 17p13(del) and 1q21(amp). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e50-e51.	0.4	1
94	Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip. <i>Npj Precision Oncology</i> , 2019, 3, 30.	5.4	23
95	Salsalate is An Active Agent in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e135.	0.4	0
96	Carfilzomib, Thalidomide and Dexamethasone (KTD) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e274-e275.	0.4	0
97	Super-enhancer profiling of multiple myeloma in search of novel oncogenes and therapeutic targets. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e67-e68.	0.4	0
98	MMSET 1 acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. <i>Leukemia</i> , 2019, 33, 739-748.	7.2	13
99	Towards understanding of PRC2 binding to RNA. <i>RNA Biology</i> , 2019, 16, 176-184.	3.1	40
100	Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. <i>Haematologica</i> , 2019, 104, 1209-1220.	3.5	30
101	Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. <i>British Journal of Haematology</i> , 2019, 186, 162-165.	2.5	2
102	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
103	Non-canonical activation of β -catenin by PRL-3 phosphatase in acute myeloid leukemia. <i>Oncogene</i> , 2019, 38, 1508-1519.	5.9	17
104	Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone. <i>Blood</i> , 2019, 134, 4376-4376.	1.4	1
105	Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. <i>World Journal of Clinical Oncology</i> , 2019, 10, 303-306.	2.3	10
106	Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 5253-5253.	1.4	0
107	Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma. <i>Blood</i> , 2019, 134, 362-362.	1.4	1
108	Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis. <i>Blood</i> , 2019, 134, 5177-5177.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE). <i>Blood</i> , 2019, 134, 5577-5577.	1.4	0
110	Cancer in 2019 - Progress and Challenges - A Perspective. <i>Annals of the Academy of Medicine, Singapore</i> , 2019, 48, 45-47.	0.4	0
111	Paraprotein interference in the diagnosis of hepatitis C infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e194-e196.	2.3	0
112	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
113	Large-scale expansion of V β 9V α 2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells. <i>Cytotherapy</i> , 2018, 20, 420-435.	0.7	43
114	Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 225-232.	0.9	3
115	The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 159-168.	1.5	21
116	X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery. <i>Molecular Oncology</i> , 2018, 12, 33-47.	4.6	15
117	Neutrophils differentially attenuate immune response to <i>Aspergillus</i> infection through complement receptor 3 and induction of myeloperoxidase. <i>Cellular Microbiology</i> , 2018, 20, e12798.	2.1	6
118	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	1.3	6
119	CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay. <i>Journal of Clinical Pathology</i> , 2018, 71, 522-531.	2.0	15
120	Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. <i>Haematologica</i> , 2018, 103, 278-287.	3.5	82
121	The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. <i>Cancers</i> , 2018, 10, 327.	3.7	94
122	Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S248-S249.	0.4	0
123	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XLO19 and vorinostat. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 593-619.	5.5	33
124	Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. <i>Blood</i> , 2018, 132, 1304-1317.	1.4	67
125	ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3931-3941.	5.4	14
126	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. <i>Blood</i> , 2018, 132, 1146-1158.	1.4	218

#	ARTICLE	IF	CITATIONS
127	BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia. BMC Cancer, 2018, 18, 731.	2.6	16
128	Potential Clinical Application of Genomics in Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 1721.	4.1	5
129	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. International Journal of Molecular Sciences, 2018, 19, 1931.	4.1	28
130	A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/ β -catenin pathways for treatment of AML with high PRL-3 phosphatase. Journal of Hematology and Oncology, 2018, 11, 36.	17.0	22
131	Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. International Journal of Antimicrobial Agents, 2018, 52, 350-357.	2.5	5
132	Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Science Translational Medicine, 2018, 10, .	12.4	80
133	Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity. Blood, 2018, 132, 2676-2676.	1.4	5
134	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	1.4	9
135	CD55 and CD59 Can Limit the Anti-Tumor Efficacy of Daratumumab in Natural Killer/T-Cell Lymphoma. Blood, 2018, 132, 1663-1663.	1.4	3
136	Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report. Blood, 2018, 132, 5237-5237.	1.4	2
137	LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget, 2018, 9, 31832-31841.	1.8	13
138	NF- κ B promotes the stem-like properties of leukemia cells by activation of LIN28B. World Journal of Stem Cells, 2018, 10, 34-42.	2.8	8
139	Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World Journal of Clinical Oncology, 2018, 9, 90-97.	2.3	16
140	Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. Blood, 2018, 132, 3251-3251.	1.4	0
141	NSD2 Interacts with SMARCA2 and Regulates Expression of Oncogenes CCND1 and PRL3 in T(4;14) Multiple Myeloma. Blood, 2018, 132, 4479-4479.	1.4	0
142	Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies. Blood, 2018, 132, 5637-5637.	1.4	0
143	Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma. Blood, 2018, 132, 4513-4513.	1.4	0
144	Epidemiology of Patients with Classical Philadelphia-Chromosome Negative Myeloproliferative Neoplasms at a Single Academic Medical Center in Singapore. Blood, 2018, 132, 5478-5478.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Evaluation of Maintenance Therapy in Myeloma in an Asian Population. <i>Blood</i> , 2018, 132, 3231-3231.	1.4	0
146	Overexpressed Melk Promotes the Stability of EZH2 through Phosphorylation in Natural Killer/T Cell Lymphoma (NKTL). <i>Blood</i> , 2018, 132, 2858-2858.	1.4	0
147	Single-cell genomic profiling of acute myeloid leukemia for clinical use: A pilot study. <i>Oncology Letters</i> , 2017, 13, 1625-1630.	1.8	13
148	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	10.7	394
149	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	1.3	22
150	LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. <i>Molecular Cancer Research</i> , 2017, 15, 294-303.	3.4	29
151	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8336-8357.	6.4	82
152	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
153	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	10.7	320
154	Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. <i>Stem Cell Investigation</i> , 2017, 4, 6-6.	3.0	36
155	VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. <i>Oncotarget</i> , 2017, 8, 101847-101864.	1.8	5
156	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.	0.6	6
157	Tumor-derived exosomes in colorectal cancer progression and their clinical applications. <i>Oncotarget</i> , 2017, 8, 100781-100790.	1.8	48
158	The emerging roles of exosomes in leukemogenesis. <i>Oncotarget</i> , 2016, 7, 50698-50707.	1.8	33
159	Isochromosome 17q; A Novel Finding in Myeloid Sarcoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 130-134.	0.8	1
160	Carfilzomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e126.	10.7	4
161	Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. <i>Cancer Biology and Therapy</i> , 2016, 17, 723-726.	3.4	2
162	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	1.4	686

#	ARTICLE	IF	CITATIONS
163	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. <i>Blood</i> , 2016, 128, 948-958.	1.4	110
164	Molecular switch of EZH2 in hypoxia. <i>Cell Cycle</i> , 2016, 15, 3007-3008.	2.6	6
165	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. <i>Lancet Oncology</i> , The, 2016, 17, 1240-1247.	10.7	84
166	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8233-8262.	6.4	78
167	Activation of mutant <i>TERT</i> promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14402-14407.	7.1	81
168	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	10.7	1,866
169	Transplant Outcomes and Early Relapse after Novel and Non-Novel Agent Induction: An Analysis By Singapore Myeloma Working Group. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S221.	2.0	0
170	HIF1 α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3735-44.	7.1	62
171	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
172	Risk Stratification in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 137-147.	2.3	21
173	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
174	PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. <i>Oncotarget</i> , 2016, 7, 61806-61819.	1.8	23
175	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. <i>Oncotarget</i> , 2016, 7, 74779-74796.	1.8	16
176	Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas. <i>Oncotarget</i> , 2016, 7, 83964-83975.	1.8	5
177	Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis. <i>Blood</i> , 2016, 128, 4498-4498.	1.4	0
178	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	1.4	0
179	Outcome and Prognostic Factors of Patients with Hematological Malignancies Admitted to an Intensive Care Unit. <i>Blood</i> , 2016, 128, 4796-4796.	1.4	0
180	Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL). <i>Blood</i> , 2016, 128, 1773-1773.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. <i>Blood</i> , 2016, 128, 4650-4650.	1.4	0
182	Necrotizing Fasciitis in Hematological Patients: Enterobacteriaceae Predominance and Limited Utility of Laboratory Risk Indicator for Necrotizing Fasciitis Score. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv081.	0.9	15
183	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. <i>Blood</i> , 2015, 125, 443-448.	1.4	195
184	<i>p53</i> mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation. <i>World Journal of Gastroenterology</i> , 2015, 21, 84.	3.3	248
185	Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target. <i>Oncotarget</i> , 2015, 6, 5490-5500.	1.8	92
186	Bimodal Influence of Vitamin D in Host Response to Systemic <i>Candida</i> Infection—Vitamin D Dose Matters. <i>Journal of Infectious Diseases</i> , 2015, 212, 635-644.	4.0	26
187	Establishment and Characterization of Novel Human Primary and Metastatic Anaplastic Thyroid Cancer Cell Lines and Their Genomic Evolution Over a Year as a Primagraft. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 725-735.	3.6	22
188	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1750-1760.	4.1	46
189	Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1-12.	3.7	73
190	Role of HIF1 & ARG2 in hematological malignancy. <i>Experimental Hematology</i> , 2015, 43, S84.	0.4	0
191	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	2.6	27
192	Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype. <i>Leukemia and Lymphoma</i> , 2015, 56, 2408-2415.	1.3	7
193	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	1.4	5
194	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	1.4	8
195	The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3737-3737.	1.4	3
196	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	1.4	3
197	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	1.4	27
198	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS ONE, 2015, 10, e0122983.	2.5	18
200	High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS ONE, 2015, 10, e0142466.	2.5	19
201	Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget, 2015, 6, 26508-26518.	1.8	41
202	PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget, 2015, 6, 36689-36699.	1.8	39
203	A Rare Variant of Aggressive T-Cell Large Granular Lymphocyte Leukemia Associated With Hepatic Fibrosis and Trisomy 8: A Case Report and Literature Review. Journal of Hematology (Brossard, Tj ETQq1 1 0.7843 140gBT /Overlock 10	1.4	0
204	Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma. Blood, 2015, 126, 3103-3103.	1.4	0
205	Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population. Blood, 2015, 126, 2574-2574.	1.4	0
206	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712.	1.4	0
207	Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches. Blood, 2015, 126, 2764-2764.	1.4	0
208	Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World Journal of Stem Cells, 2014, 6, 473.	2.8	55
209	LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia. Cancer Research, 2014, 74, 3043-3053.	0.9	29
210	MMSET: Role and Therapeutic Opportunities in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-5.	1.9	21
211	MicroRNA: Important Player in the Pathobiology of Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12.	1.9	43
212	Unusual case of metachronous EBV-associated B-cell and NK/T-cell lymphoma mimicking polymyositis—diagnostic challenges and pitfalls. American Journal of Hematology, 2014, 89, 110-113.	4.1	7
213	Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study. American Journal of Hematology, 2014, 89, 751-756.	4.1	88
214	Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. Experimental Hematology, 2014, 42, 1041-1052.e2.	0.4	21
215	Modified clg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice. Cancer Genetics, 2014, 207, 31-34.	0.4	10
216	CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells. British Journal of Haematology, 2014, 165, 134-144.	2.5	8

#	ARTICLE	IF	CITATIONS
217	Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. <i>Supportive Care in Cancer</i> , 2014, 22, 1447-1451.	2.2	5
218	T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing. <i>Cancer Research</i> , 2014, 74, 93-103.	0.9	171
219	Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. <i>Cancer Letters</i> , 2014, 354, 272-280.	7.2	16
220	Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF- κ B regulated gene products in multiple myeloma xenograft mouse model. <i>Oncotarget</i> , 2014, 5, 634-648.	1.8	142
221	PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) Mediates Anti-Myeloma Effect through the ER Stress Pathway. <i>Blood</i> , 2014, 124, 2093-2093.	1.4	0
222	MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents. <i>Blood</i> , 2014, 124, 171-171.	1.4	0
223	Incidence and Clinical Features of Calreticulin mutation in Patients with Jak2V617F-Negative Essential Thrombocytosis and Primary Myelofibrosis from Singapore. <i>Blood</i> , 2014, 124, 3176-3176.	1.4	0
224	Deregulated <i>MIR335</i> that targets <i>MAPK1</i> is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 93-103.	2.5	46
225	Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1507-1514.	2.5	37
226	Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. <i>Mitochondrion</i> , 2013, 13, 163-169.	3.4	137
227	Management of multiple myeloma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e571-e581.	10.7	37
228	LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 973-978.	2.8	140
229	EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. <i>Blood</i> , 2013, 121, 4512-4520.	1.4	131
230	VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 151-161.	4.1	59
231	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , 2013, 37, 1070-1076.	0.8	15
232	ATM-dependent spontaneous regression of early E μ 1/4-myc α -induced murine B-cell leukemia depends on natural killer and T cells. <i>Blood</i> , 2013, 121, 2512-2521.	1.4	56
233	Oncogenic roles of <i>PRL3</i> in <i>FLT3</i> -induced acute myeloid leukaemia. <i>EMBO Molecular Medicine</i> , 2013, 5, 1351-1366.	6.9	44
234	A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e66361.	2.5	41

#	ARTICLE	IF	CITATIONS
235	Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 3459-3471.	8.2	62
236	Akt-Induced Phosphorylation of N-CoR at Serine 1450 Contributes to Its Misfolded Conformational Dependent Loss (MCDL) in Acute Myeloid Leukemia of the M5 Subtype. <i>PLoS ONE</i> , 2013, 8, e70891.	2.5	4
237	Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma. <i>Oncotarget</i> , 2013, 4, 1008-1018.	1.8	26
238	Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival. <i>Oncotarget</i> , 2013, 4, 1230-1240.	1.8	38
239	A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma. <i>Blood</i> , 2013, 122, 4433-4433.	1.4	0
240	Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 133-146.	1.6	0
241	Telomerase directly regulates NF- κ B-dependent transcription. <i>Nature Cell Biology</i> , 2012, 14, 1270-1281.	10.3	309
242	Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. <i>Journal of Clinical Investigation</i> , 2012, 122, 2793-2806.	8.2	87
243	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. <i>Nature Medicine</i> , 2012, 18, 521-528.	30.7	510
244	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
245	Role of Misfolded N-CoR Mediated Transcriptional Deregulation of Flt3 in Acute Monocytic Leukemia (AML)-M5 Subtype. <i>PLoS ONE</i> , 2012, 7, e34501.	2.5	8
246	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	4.1	134
247	In vivo efficacy of a novel liposomal formulation of safinol in the treatment of acute myeloid leukemia. <i>Journal of Controlled Release</i> , 2012, 160, 290-298.	9.9	21
248	Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. <i>Blood</i> , 2012, 120, 76-76.	1.4	9
249	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8097-8097.	1.6	1
250	Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. <i>Oncotarget</i> , 2012, 3, 158-171.	1.8	42
251	EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 3498-3498.	1.4	0
252	Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. <i>Blood</i> , 2012, 120, 5035-5035.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Plasma Membrane Proteomics Identifies Biomarkers Associated with T(4;14) Multiple Myeloma. <i>Blood</i> , 2012, 120, 1314-1314.	1.4	0
254	clg-FISH On Patients with Multiple Myeloma – A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service. <i>Blood</i> , 2012, 120, 4792-4792.	1.4	0
255	Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. <i>Singapore Medical Journal</i> , 2012, 53, 720-5.	0.6	7
256	TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1668-1673.	2.8	94
257	Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2011, 6, e21583.	2.5	29
258	The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. <i>Blood</i> , 2011, 118, 2830-2839.	1.4	205
259	Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF- κ B and STAT3 regulated gene products in multiple myeloma cells. <i>British Journal of Pharmacology</i> , 2011, 164, 1506-1521.	5.4	120
260	Curcumin Sensitizes Acute Promyelocytic Leukemia Cells to Unfolded Protein Response-Induced Apoptosis by Blocking the Loss of Misfolded N-CoR Protein. <i>Molecular Cancer Research</i> , 2011, 9, 878-888.	3.4	32
261	Castleman's Disease Presenting as Prolonged Anemia and Growth Retardation: A Case Report and Literature Review. <i>Acta Haematologica</i> , 2011, 125, 125-129.	1.4	3
262	C3aR1 Contributed to Acute Myeloid Leukemia Acquired Resistance to ABT-737 and Involved In the Process of AML. <i>Blood</i> , 2011, 118, 1435-1435.	1.4	1
263	A Novel Measure of Chromosome Instability Is An Independent Prognostic Factor in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1824-1824.	1.4	1
264	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. <i>Blood</i> , 2011, 118, 88-88.	1.4	3
265	PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy. <i>PLoS ONE</i> , 2011, 6, e19798.	2.5	59
266	The Pro-Metastasis Tyrosine Phosphatase, PRL-3 (PTP4A3), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 2741-2741.	1.4	0
267	Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer/T-Cell Lymphoma. <i>Blood</i> , 2011, 118, 2637-2637.	1.4	3
268	A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 1666-1666.	1.4	0
269	PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase. <i>Cancer Cell</i> , 2010, 18, 52-62.	16.8	155
270	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3534-3539.	7.1	47

#	ARTICLE	IF	CITATIONS
271	Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites. <i>Blood</i> , 2010, 116, 4160-4160.	1.4	0
272	The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML. <i>Blood</i> , 2010, 116, 4355-4355.	1.4	0
273	Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. <i>Blood</i> , 2009, 113, 4052-4062.	1.4	144
274	Gene Expression Profiling Reveals Activation of Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis of Extranodal Nasal-Type NK/T Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3931-3931.	1.4	0
275	MYC Activation Is a Common Transformation Event in Myeloma and Associated with Poor Prognosis.. <i>Blood</i> , 2009, 114, 834-834.	1.4	0
276	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. <i>Cancer Cell</i> , 2008, 13, 167-180.	16.8	322
277	Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.. <i>Blood</i> , 2008, 112, 1663-1663.	1.4	1
278	Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP).. <i>Blood</i> , 2008, 112, 1673-1673.	1.4	3
279	Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.. <i>Blood</i> , 2008, 112, 1618-1618.	1.4	0
280	Recurrent Chromosome Abnormalities Define Non-Overlapping, Unique Subgroups of Tumors in Chronic Lymphocytic Leukemia Patients with Known Karyotypic Abnormalities. <i>Blood</i> , 2008, 112, 4176-4176.	1.4	0
281	Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.. <i>Blood</i> , 2008, 112, 1682-1682.	1.4	0
282	Gene Expression Profiling of Post-Follicular B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 617-617.	1.4	0
283	Promiscuous Mutations Activate the Noncanonical NF- κ B Pathway in Multiple Myeloma. <i>Cancer Cell</i> , 2007, 12, 131-144.	16.8	941
284	RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines.. <i>Blood</i> , 2007, 110, 2489-2489.	1.4	2
285	PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NF κ B.. <i>Blood</i> , 2007, 110, 671-671.	1.4	1
286	Genomic-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 396-396.	1.4	0
287	Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.. <i>Blood</i> , 2007, 110, 2491-2491.	1.4	0
288	RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.. <i>Blood</i> , 2007, 110, 2478-2478.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Identification of Vacuolar H ⁺ -ATPase as a Target for Myeloma Therapeutics.. Blood, 2007, 110, 257-257.	1.4	0
290	High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib.. Blood, 2007, 110, 4763-4763.	1.4	0
291	Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma.. Blood, 2007, 110, 392-392.	1.4	1
292	Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis.. Blood, 2007, 110, 2490-2490.	1.4	0
293	Comparative High Resolution Array-Based CGH (aCGH) in B-Cell Malignancies.. Blood, 2007, 110, 2479-2479.	1.4	0
294	Promiscuous Mutations Frequently Activate the Non-Canonical NFκB Pathway in Multiple Myeloma (MM).. Blood, 2006, 108, 109-109.	1.4	2
295	Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.. Blood, 2006, 108, 132-132.	1.4	3
296	High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.. Blood, 2006, 108, 2093-2093.	1.4	0
297	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	1.4	0
298	Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possible Tumorigenic Mechanism in Myeloma.. Blood, 2006, 108, 113-113.	1.4	1
299	A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma.. Blood, 2006, 108, 3388-3388.	1.4	0
300	Targeted Therapy in Multiple Myeloma. Cancer Control, 2005, 12, 91-104.	1.8	27
301	Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.. Blood, 2005, 106, 508-508.	1.4	2
302	Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM).. Blood, 2005, 106, 1539-1539.	1.4	0
303	Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes.. Blood, 2005, 106, 3006-3006.	1.4	0
304	Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. Blood, 2005, 106, 624-624.	1.4	1
305	Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma.. Blood, 2005, 106, 5102-5102.	1.4	0
306	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma.. Blood, 2005, 106, 1537-1537.	1.4	0
308	Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells.. Blood, 2005, 106, 1555-1555.	1.4	0
309	Gene Expression Profiling of Hyperdiploid Multiple Myeloma Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature.. Blood, 2005, 106, 1538-1538.	1.4	8
310	Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms.. Blood, 2005, 106, 3480-3480.	1.4	0
311	One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q.. Blood, 2005, 106, 1546-1546.	1.4	0
312	Translocation (8;22) in cold agglutinin disease associated with B-cell lymphoma. Cancer Genetics and Cytogenetics, 2004, 152, 66-69.	1.0	13
313	Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. Frontiers in Oncology, 0, 12, .	2.8	5